Prevalence and patterns of medication use in children and adolescents with autism spectrum disorders in the Western Cape, South Africa

Journal of Child and Adolescent Mental Health

Volumn 25, Issue 1, 2013, Pages 69-79

  Louw, Kerry Ann ^a   Bentley, Judith ^a   Sorsdahl, Katherine ^a   Adnams, Colleen M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; BECLOMETASONE; CENTRAL STIMULANT AGENT; CETIRIZINE; CLOBAZAM; CORTICOSTEROID; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LAXATIVE; LEVOTHYROXINE SODIUM; LITHIUM; METHYLPHENIDATE; MINERAL; MONTELUKAST; MOOD STABILIZER; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; PREDNISONE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VITAMIN; ZIPRASIDONE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE DISTRIBUTION; ALTERNATIVE MEDICINE; ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; ASIAN; AUTISM; BEHAVIOR DISORDER; CAUCASIAN; CHILD; CHILD BEHAVIOR; DEPRESSION; DIET SUPPLEMENTATION; DRUG INDICATION; DRUG USE; EMOTIONAL DISORDER; ETHNIC DIFFERENCE; FEMALE; HEALTH SURVEY; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERSALIVATION; INCOME; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MUSCLE SPASM; NAUSEA; NEGRO; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; PSYCHOSIS; SCHOOL CHILD; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOUTH AFRICA; VOMITING; WEIGHT GAIN;

EID: 84879080760     PISSN: 17280583     EISSN: 17280591     Source Type: Journal    
DOI: 10.2989/17280583.2013.767265     Document Type: Article

References (27)

1. Akins RS, Angkustsiri K, Hansen RL. 2010. Complementary and alternative medicine in autism: an evidencebased approach to negotiating safe and efficacious interventions with families. Neurotherapeutics 7: 307-319.
2. Aman MG, Lam KS, Collier-Crespin A. 2003. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders 33: 527-534.
3. Aman MG, Tasse MJ, Rojahn J, Hammer D. 1996. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities 17: 41-57.
4. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G. 1995. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry 34: 1672-1681.
5. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. (4th edn, Text Revision). Arlington: American Psychiatric Association.
6. Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, Chandra M, Reed G, Gurwitz JH. 2011. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics 128: 1135-1141.
7. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T. 2006. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368: 210-215.
8. Food and Drug Administration. 2006. FDA approves the first drug to treat irritability associated with autism, Risperdal. Food and Drug Administration News Release 6 October.
9. Hanson E, Kalish LA, Bunce E, Curtis C, McDaniel S, Ware J, Petry J. 2007. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. Journal of Autism and Developmental Disorders 37: 628-636.
10. Huffman LC, Sutcliffe TL, Tanner IS, Feldman HM. 2011. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicinetreatments. Journal of Developmental and Behavioural Pediatrics 32: 56-68.
11. Hyman S, Levy S. 2000. Autistic spectrum disorders: When traditional medicine is not enough. Contemporary Pediatrics 17: 100-114.
12. Kwok HWM. 2003. Psychopharmacology in Autism Spectrum Disorders. Current Opinion in Psychiatry 16: 529-534.
13. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. 2002. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 12: 311-321.
14. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. 2008. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 121: e441-e448.
15. MAPI Institute. MAPI Institute online. 2009. September 19. Available at http://www.mapi-institute.com/quetionnaires-and-translation/ourcatalog/ 130-specific-questionnaires-pediatrics [accessed 19 September 2009].
16. Martin A, Scahill L, Klin A, Volkmar FR. 1999. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. Journal of the American Academy of Child and Adolescent Psychiatry 38: 923-931.
17. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J. 2011. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127: e1312-e1321.
18. Oswald DP, Sonenklar NA. 2007. Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology 17: 348-355.
19. Rosenberg RE, Mandell DS, Farmer JE, Law JK, Marvin AR, Law PA. 2010. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. Journal of Autism and Developmental Disorders 40: 342-351.
20. Schopler E, Reichler RJ, DeVellis RF, Daly K. 1980. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders 10: 91-103.
21. Siegel M, Beaulieu AA. 2012. Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice. Journal of Autism and Developmental Disorders 42: 1592-1606.
22. Steyn B, Le Couteur A. 2003. Understanding autism spectrum disorders. Current Pediatrics 13: 274-278.
23. Tasse MJ, Aman MG, Hammer D, Rojahn J. 1996. The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Research in Developmental Disabilities 17: 59-75.
24. Warren Z, McPheeters ML, Sathe N, Foss-Feig JH, Glasser A, Veenstra-Vanderweele J. 2011a. A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics 127: e1303-e1311.
25. Warren Z, Veenstra-Vanderweele J, Stone W, Bruzek JL, Nahmias AS, Foss-Feig JH, Jerome RN, Krishnaswami S, Sathe NA, Glasser AM et al. 2011b. Therapies for children with autism spectrum disorders. Comparative Effectiveness Review No. 26. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publication No. 11-EHC029-EF. Rockville, Madison: Agency for Healthcare Research and Quality, April 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final. cfm [accessed January 2012].
26. Witwer A, Lecavalier L. 2005. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology 15: 671-681.
27. Wong HH, Smith RG. 2006. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. Journal of Autism and Developmental Disorders 36: 901-909.